Professional role
a co-founder and advisor to ALZPath[1]
ER
a former member of the National Advisory Council on Aging (NIA Council)
an author of more than 650 publications
a principal investigator of several large NIH, state, and foundation grants and contracts
a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease
His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.
brain imaging, blood-based biomarkers, APOE and genomics research · the accelerated evaluation of Alzheimer’s prevention therapies · the establishment of new models of research collaboration and clinical care · the unusually early detection, tracking, and study of Alzheimer’s disease
Reviewed sources document brain imaging, blood-based biomarkers, APOE and genomics research, the accelerated evaluation of Alzheimer’s prevention therapies, the establishment of new models of research collaboration and clinical care, and the unusually early detection, tracking, and study of Alzheimer’s disease. Explore attributed publications and research affiliations.
Explore researcha co-founder and advisor to ALZPath[1]
advisor[1]
a leader of the Alzheimer’s Prevention Initiative (API)[1]
A psychiatrist[1]
brain imaging researcher[1]
CEO of Banner Research[1]
Chairman of the Board of the Flinn Foundation[1]
Director[1]
Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC)[1]
Executive Director[1]
Executive Director of Banner Alzheimer’s Institute[1]
principal investigator[1]
Senior Scientist[1]
Senior Scientist at the Translational Genomics Research Institute[1]
brain imaging, blood-based biomarkers, APOE and genomics research[1]
the accelerated evaluation of Alzheimer’s prevention therapies[1]
the establishment of new models of research collaboration and clinical care[1]
the unusually early detection, tracking, and study of Alzheimer’s disease[1]
Sources are listed once and connected to each accepted claim they support. Excerpts preserve the source language used in the review.
26 source claims · Reviewed Sep 9, 2026
Biographical context: a former member of the National Advisory Council on Aging (NIA Council)
Eric Reiman, MD, is Executive Director of Banner Alzheimer’s Institute, CEO of Banner Research, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). He is also a co-founder and advisor to ALZPath, a start-up company that aims to advance the role of blood tests in the scientific and clinical fight against Alzheimer’s disease, and Chairman of the Board of the Flinn Foundation. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and the establishment of new models of research collaboration and clinical care. He is an author of more than 650 publications, a principal investigator of several large NIH, state, and foundation grants and contracts, a former member of the National Advisory Council on Aging (NIA Council), and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease. His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.
Biographical context: an author of more than 650 publications
He is an author of more than 650 publications
Biographical context: a principal investigator of several large NIH, state, and foundation grants and contracts
Eric Reiman, MD, is Executive Director of Banner Alzheimer’s Institute, CEO of Banner Research, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). He is also a co-founder and advisor to ALZPath, a start-up company that aims to advance the role of blood tests in the scientific and clinical fight against Alzheimer’s disease, and Chairman of the Board of the Flinn Foundation. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and the establishment of new models of research collaboration and clinical care. He is an author of more than 650 publications, a principal investigator of several large NIH, state, and foundation grants and contracts, a former member of the National Advisory Council on Aging (NIA Council), and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease. His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.
Biographical context: a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease
Eric Reiman, MD, is Executive Director of Banner Alzheimer’s Institute, CEO of Banner Research, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). He is also a co-founder and advisor to ALZPath, a start-up company that aims to advance the role of blood tests in the scientific and clinical fight against Alzheimer’s disease, and Chairman of the Board of the Flinn Foundation. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and the establishment of new models of research collaboration and clinical care. He is an author of more than 650 publications, a principal investigator of several large NIH, state, and foundation grants and contracts, a former member of the National Advisory Council on Aging (NIA Council), and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease. His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.
Biographical context: His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.
Eric Reiman, MD, is Executive Director of Banner Alzheimer’s Institute, CEO of Banner Research, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). He is also a co-founder and advisor to ALZPath, a start-up company that aims to advance the role of blood tests in the scientific and clinical fight against Alzheimer’s disease, and Chairman of the Board of the Flinn Foundation. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and the establishment of new models of research collaboration and clinical care. He is an author of more than 650 publications, a principal investigator of several large NIH, state, and foundation grants and contracts, a former member of the National Advisory Council on Aging (NIA Council), and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease. His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.
Degree: MD
Eric Reiman, MD, is Executive Director of Banner Alzheimer’s Institute, CEO of Banner Research, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). He is also a co-founder and advisor to ALZPath, a start-up company that aims to advance the role of blood tests in the scientific and clinical fight against Alzheimer’s disease, and Chairman of the Board of the Flinn Foundation. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and the establishment of new models of research collaboration and clinical care. He is an author of more than 650 publications, a principal investigator of several large NIH, state, and foundation grants and contracts, a former member of the National Advisory Council on Aging (NIA Council), and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease. His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.
Identity: Eric Reiman, MD
Eric Reiman, MD, is Executive Director of Banner Alzheimer’s Institute, CEO of Banner Research, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). He is also a co-founder and advisor to ALZPath, a start-up company that aims to advance the role of blood tests in the scientific and clinical fight against Alzheimer’s disease, and Chairman of the Board of the Flinn Foundation. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and the establishment of new models of research collaboration and clinical care. He is an author of more than 650 publications, a principal investigator of several large NIH, state, and foundation grants and contracts, a former member of the National Advisory Council on Aging (NIA Council), and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease. His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.
Professional role: a co-founder and advisor to ALZPath
Eric Reiman, MD, is Executive Director of Banner Alzheimer’s Institute, CEO of Banner Research, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). He is also a co-founder and advisor to ALZPath, a start-up company that aims to advance the role of blood tests in the scientific and clinical fight against Alzheimer’s disease, and Chairman of the Board of the Flinn Foundation. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and the establishment of new models of research collaboration and clinical care. He is an author of more than 650 publications, a principal investigator of several large NIH, state, and foundation grants and contracts, a former member of the National Advisory Council on Aging (NIA Council), and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease. His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.
Professional role: advisor
Eric Reiman, MD, is Executive Director of Banner Alzheimer’s Institute, CEO of Banner Research, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). He is also a co-founder and advisor to ALZPath, a start-up company that aims to advance the role of blood tests in the scientific and clinical fight against Alzheimer’s disease, and Chairman of the Board of the Flinn Foundation. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and the establishment of new models of research collaboration and clinical care. He is an author of more than 650 publications, a principal investigator of several large NIH, state, and foundation grants and contracts, a former member of the National Advisory Council on Aging (NIA Council), and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease. His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.
Professional role: a leader of the Alzheimer’s Prevention Initiative (API)
Eric Reiman, MD, is Executive Director of Banner Alzheimer’s Institute, CEO of Banner Research, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). He is also a co-founder and advisor to ALZPath, a start-up company that aims to advance the role of blood tests in the scientific and clinical fight against Alzheimer’s disease, and Chairman of the Board of the Flinn Foundation. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and the establishment of new models of research collaboration and clinical care. He is an author of more than 650 publications, a principal investigator of several large NIH, state, and foundation grants and contracts, a former member of the National Advisory Council on Aging (NIA Council), and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease. His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.
Professional role: A psychiatrist
Eric Reiman, MD, is Executive Director of Banner Alzheimer’s Institute, CEO of Banner Research, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). He is also a co-founder and advisor to ALZPath, a start-up company that aims to advance the role of blood tests in the scientific and clinical fight against Alzheimer’s disease, and Chairman of the Board of the Flinn Foundation. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and the establishment of new models of research collaboration and clinical care. He is an author of more than 650 publications, a principal investigator of several large NIH, state, and foundation grants and contracts, a former member of the National Advisory Council on Aging (NIA Council), and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease. His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.
Professional role: brain imaging researcher
Eric Reiman, MD, is Executive Director of Banner Alzheimer’s Institute, CEO of Banner Research, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). He is also a co-founder and advisor to ALZPath, a start-up company that aims to advance the role of blood tests in the scientific and clinical fight against Alzheimer’s disease, and Chairman of the Board of the Flinn Foundation. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and the establishment of new models of research collaboration and clinical care. He is an author of more than 650 publications, a principal investigator of several large NIH, state, and foundation grants and contracts, a former member of the National Advisory Council on Aging (NIA Council), and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease. His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.
Professional role: CEO of Banner Research
Eric Reiman, MD, is Executive Director of Banner Alzheimer’s Institute, CEO of Banner Research, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). He is also a co-founder and advisor to ALZPath, a start-up company that aims to advance the role of blood tests in the scientific and clinical fight against Alzheimer’s disease, and Chairman of the Board of the Flinn Foundation. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and the establishment of new models of research collaboration and clinical care. He is an author of more than 650 publications, a principal investigator of several large NIH, state, and foundation grants and contracts, a former member of the National Advisory Council on Aging (NIA Council), and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease. His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.
Professional role: Chairman of the Board of the Flinn Foundation
Eric Reiman, MD, is Executive Director of Banner Alzheimer’s Institute, CEO of Banner Research, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). He is also a co-founder and advisor to ALZPath, a start-up company that aims to advance the role of blood tests in the scientific and clinical fight against Alzheimer’s disease, and Chairman of the Board of the Flinn Foundation. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and the establishment of new models of research collaboration and clinical care. He is an author of more than 650 publications, a principal investigator of several large NIH, state, and foundation grants and contracts, a former member of the National Advisory Council on Aging (NIA Council), and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease. His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.
Professional role: Director
Eric Reiman, MD, is Executive Director of Banner Alzheimer’s Institute, CEO of Banner Research, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). He is also a co-founder and advisor to ALZPath, a start-up company that aims to advance the role of blood tests in the scientific and clinical fight against Alzheimer’s disease, and Chairman of the Board of the Flinn Foundation. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and the establishment of new models of research collaboration and clinical care. He is an author of more than 650 publications, a principal investigator of several large NIH, state, and foundation grants and contracts, a former member of the National Advisory Council on Aging (NIA Council), and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease. His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.
Professional role: Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC)
Eric Reiman, MD, is Executive Director of Banner Alzheimer’s Institute, CEO of Banner Research, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). He is also a co-founder and advisor to ALZPath, a start-up company that aims to advance the role of blood tests in the scientific and clinical fight against Alzheimer’s disease, and Chairman of the Board of the Flinn Foundation. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and the establishment of new models of research collaboration and clinical care. He is an author of more than 650 publications, a principal investigator of several large NIH, state, and foundation grants and contracts, a former member of the National Advisory Council on Aging (NIA Council), and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease. His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.
Professional role: Executive Director
Eric Reiman, MD, is Executive Director of Banner Alzheimer’s Institute, CEO of Banner Research, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). He is also a co-founder and advisor to ALZPath, a start-up company that aims to advance the role of blood tests in the scientific and clinical fight against Alzheimer’s disease, and Chairman of the Board of the Flinn Foundation. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and the establishment of new models of research collaboration and clinical care. He is an author of more than 650 publications, a principal investigator of several large NIH, state, and foundation grants and contracts, a former member of the National Advisory Council on Aging (NIA Council), and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease. His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.
Professional role: Executive Director of Banner Alzheimer’s Institute
Eric Reiman, MD, is Executive Director of Banner Alzheimer’s Institute, CEO of Banner Research, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). He is also a co-founder and advisor to ALZPath, a start-up company that aims to advance the role of blood tests in the scientific and clinical fight against Alzheimer’s disease, and Chairman of the Board of the Flinn Foundation. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and the establishment of new models of research collaboration and clinical care. He is an author of more than 650 publications, a principal investigator of several large NIH, state, and foundation grants and contracts, a former member of the National Advisory Council on Aging (NIA Council), and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease. His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.
Professional role: principal investigator
Eric Reiman, MD, is Executive Director of Banner Alzheimer’s Institute, CEO of Banner Research, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). He is also a co-founder and advisor to ALZPath, a start-up company that aims to advance the role of blood tests in the scientific and clinical fight against Alzheimer’s disease, and Chairman of the Board of the Flinn Foundation. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and the establishment of new models of research collaboration and clinical care. He is an author of more than 650 publications, a principal investigator of several large NIH, state, and foundation grants and contracts, a former member of the National Advisory Council on Aging (NIA Council), and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease. His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.
Professional role: Senior Scientist
Eric Reiman, MD, is Executive Director of Banner Alzheimer’s Institute, CEO of Banner Research, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). He is also a co-founder and advisor to ALZPath, a start-up company that aims to advance the role of blood tests in the scientific and clinical fight against Alzheimer’s disease, and Chairman of the Board of the Flinn Foundation. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and the establishment of new models of research collaboration and clinical care. He is an author of more than 650 publications, a principal investigator of several large NIH, state, and foundation grants and contracts, a former member of the National Advisory Council on Aging (NIA Council), and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease. His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.
Professional role: Senior Scientist at the Translational Genomics Research Institute
Eric Reiman, MD, is Executive Director of Banner Alzheimer’s Institute, CEO of Banner Research, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). He is also a co-founder and advisor to ALZPath, a start-up company that aims to advance the role of blood tests in the scientific and clinical fight against Alzheimer’s disease, and Chairman of the Board of the Flinn Foundation. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and the establishment of new models of research collaboration and clinical care. He is an author of more than 650 publications, a principal investigator of several large NIH, state, and foundation grants and contracts, a former member of the National Advisory Council on Aging (NIA Council), and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease. His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.
Official profile: Official profile
Eric Reiman, MD, is Executive Director of Banner Alzheimer’s Institute, CEO of Banner Research, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). He is also a co-founder and advisor to ALZPath, a start-up company that aims to advance the role of blood tests in the scientific and clinical fight against Alzheimer’s disease, and Chairman of the Board of the Flinn Foundation. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and the establishment of new models of research collaboration and clinical care. He is an author of more than 650 publications, a principal investigator of several large NIH, state, and foundation grants and contracts, a former member of the National Advisory Council on Aging (NIA Council), and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease. His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.
Research interests: brain imaging, blood-based biomarkers, APOE and genomics research
his interests include brain imaging, blood-based biomarkers, APOE and genomics research
Research interests: the accelerated evaluation of Alzheimer’s prevention therapies
Eric Reiman, MD, is Executive Director of Banner Alzheimer’s Institute, CEO of Banner Research, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). He is also a co-founder and advisor to ALZPath, a start-up company that aims to advance the role of blood tests in the scientific and clinical fight against Alzheimer’s disease, and Chairman of the Board of the Flinn Foundation. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and the establishment of new models of research collaboration and clinical care. He is an author of more than 650 publications, a principal investigator of several large NIH, state, and foundation grants and contracts, a former member of the National Advisory Council on Aging (NIA Council), and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease. His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.
Research interests: the establishment of new models of research collaboration and clinical care
Eric Reiman, MD, is Executive Director of Banner Alzheimer’s Institute, CEO of Banner Research, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). He is also a co-founder and advisor to ALZPath, a start-up company that aims to advance the role of blood tests in the scientific and clinical fight against Alzheimer’s disease, and Chairman of the Board of the Flinn Foundation. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and the establishment of new models of research collaboration and clinical care. He is an author of more than 650 publications, a principal investigator of several large NIH, state, and foundation grants and contracts, a former member of the National Advisory Council on Aging (NIA Council), and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease. His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.
Research interests: the unusually early detection, tracking, and study of Alzheimer’s disease
Eric Reiman, MD, is Executive Director of Banner Alzheimer’s Institute, CEO of Banner Research, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). He is also a co-founder and advisor to ALZPath, a start-up company that aims to advance the role of blood tests in the scientific and clinical fight against Alzheimer’s disease, and Chairman of the Board of the Flinn Foundation. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and the establishment of new models of research collaboration and clinical care. He is an author of more than 650 publications, a principal investigator of several large NIH, state, and foundation grants and contracts, a former member of the National Advisory Council on Aging (NIA Council), and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, study, and prevention of Alzheimer’s disease. His overarching goal is to find and support the approval and widespread availability of effective Alzheimer’s prevention therapies within the next three years.